CDTX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	199 489
平均成交量	58 335.00
市值	57.61M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-1.500 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.43
ATR14	$0.0870 (0.69%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Ward Shane	Buy	120 000	Common Stock
2024-03-15	Ward Shane	Buy	250 000	Employee Stock Option (right to buy)
2024-03-15	Shah Preetam	Buy	108 750	Common Stock
2024-03-15	Shah Preetam	Buy	217 500	Employee Stock Option (right to buy)
2024-03-15	Tari Leslie	Buy	111 250	Common Stock

INSIDER POWER
89.46
Last 100 transactions
Buy: 7 175 633 \| Sell: 576 273

音量相关性

長: -0.10 (neutral)

短: -0.27 (neutral)

Signal:(38.021) Neutral

Cidara Therapeutics Inc 相关性

10 最正相关
MESA	0.902
ATHX	0.885
CTIB	0.882
IGTA	0.876
HLIO	0.873
IOBT	0.859
XLNX	0.857
TITN	0.855
KZR	0.854
AZYO	0.853

10 最负相关
NTUS	-0.89
DVCR	-0.876
OPNT	-0.869
JJSF	-0.867
SVOK	-0.866
LMNX	-0.861
PROC	-0.856
STAY	-0.852
DSPG	-0.843
MSON	-0.842

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cidara Therapeutics Inc 相关性 - 货币/商品

0.49
( neutral )

0.48
( neutral )

0.00
( neutral )

-0.13
( neutral )

0.02
( neutral )

-0.27
( neutral )

Cidara Therapeutics Inc 财务报表

Annual	2023
营收:	$63.91M
毛利润:	$62.38M (97.62 %)
EPS:	$-0.260

FY	2023
营收:	$63.91M
毛利润:	$62.38M (97.62 %)
EPS:	$-0.260

FY	2022
营收:	$64.29M
毛利润:	$64.15M (99.78 %)
EPS:	$-0.430

FY	2021
营收:	$49.57M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Cidara Therapeutics Inc

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.